Article
Endocrinology & Metabolism
Eva C. Coopmans, Aart J. van der Lely, Sebastian J. C. M. M. Neggers
Summary: Acromegaly is a chronic disorder caused by GH-producing pituitary adenoma. While surgery and medical therapy are standard treatments, some tumors behave aggressively and are resistant to these therapies. In such cases, multimodal therapeutic strategies should be considered.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Susan L. Samson, Lisa B. Nachtigall, Maria Fleseriu, Mojca Jensterle, Patrick J. Manning, Atanaska Elenkova, Mark E. Molitch, William H. Ludlam, Gary Patou, Asi Haviv, Nienke R. Biermasz, Andrea Giustina, Christian J. Strasburger, Laurence Kennedy, Shlomo Melmed
Summary: This study reports the long-term durability of therapeutic response in adults with acromegaly receiving oral octreotide capsules (OOC). The results show that patients maintained a biochemical response while receiving OOC and no new adverse events were observed with prolonged OOC exposure.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2022)
Review
Medicine, General & Internal
Nazanin Ershadinia, Nicholas A. Tritos
Summary: Acromegaly is a condition caused by a pituitary adenoma that secretes growth hormone, resulting in various complications. Early diagnosis and appropriate treatment are crucial. Diagnosis is confirmed through biochemical tests and MRI. Pituitary surgery is usually the first-line treatment, while medical therapy and radiation therapy can be used as adjunct options.
MAYO CLINIC PROCEEDINGS
(2022)
Review
Endocrinology & Metabolism
Christos Papaioannou, Maralyn Druce
Summary: This review analyzes and evaluates the current evidence for the use of preoperative medications and different surgical approaches in acromegaly. The use of somatostatin receptor agonists (SAs) as preoperative treatment for acromegaly is controversial, with guidelines suggesting against their routine use. However, SAs have been found to reduce tumor volume and aid in total adenoma resection for invasive macroadenomas. Furthermore, endoscopic transsphenoidal surgery is considered the optimal method for hypophysectomy in terms of remission and safety profile.
CLINICAL ENDOCRINOLOGY
(2023)
Review
Medicine, Research & Experimental
Jacobo Kerbel, Amayrani Cano-Zaragoza, Rodrigo Espinosa-Dorado, Keren-Enid Garcia de la Torre, Moises Mercado
Summary: National registries are valuable tools to investigate rare conditions like acromegaly, providing insights into epidemiology, clinical presentation, diagnosis, treatment outcomes, and mortality. While single-center studies are more homogeneous, they are often limited by small sample sizes and lack statistical power.
ARCHIVES OF MEDICAL RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Joan Gil, Montserrat Marques-Pamies, Elena Valassi, Araceli Garcia-Martinez, Guillermo Serra, Cristina Hostalot, Carmen Fajardo-Montanana, Cristina Carrato, Ignacio Bernabeu, Monica Marazuela, Helena Rodriguez-Lloveras, Rosa Camara, Isabel Salinas, Cristina Lamas, Betina Biagetti, Andreu Simo-Servat, Susan M. Webb, Antonio Pico, Mireia Jorda, Manel Puig-Domingo
Summary: Acromegaly is a condition caused by excessive growth hormone production due to a pituitary tumor. This study examines the relationship between epithelial-mesenchymal transition (EMT) and resistance to somatostatin receptor ligands (SRLs) in GH-producing tumors. The findings suggest that EMT-related gene expression patterns are heterogeneous, which may explain the varying responses to SRLs.
Review
Endocrinology & Metabolism
Monica R. Gadelha, Luiz Eduardo Wildemberg, Leandro Kasuki
Summary: This article discusses the future perspectives of currently available SRLs, including the use of biomarkers of response and precision medicine, new formulations of these SRLs, and new drugs under development. Precision medicine based on biomarkers of response can help improve treatment decision-making and response rates. New formulations may improve patients' adherence to treatment and quality of life. New drugs may present higher efficacy than currently available drugs.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Endocrinology & Metabolism
Yamei Yang, Jie Liu, Kan Deng, Lin Lu, Huijuan Zhu, Xiaolan Lian, Xinjie Bao, Lian Duan, Yong Yao
Summary: Adolescent-onset TSH-oma patients presented with higher levels of TSH and thyroid hormones, more large tumors, and poorer treatment outcomes compared to adult cases. Early diagnosis, multidisciplinary therapy, and close follow-up are important for improving the prognosis.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
Frederique Albarel, Thomas Cuny, Thomas Graillon, Henry Dufour, Thierry Brue, Frederic Castinetti
Summary: Transsphenoidal surgery is the primary treatment for acromegaly, but surgical remission rates can be affected by various factors. The benefits of presurgical medical treatment using somatostatin receptor ligands (SRLs) are still unclear, but it may improve patient condition and decrease surgical complications by normalizing hormone levels and reducing tumor size.
JOURNAL OF THE ENDOCRINE SOCIETY
(2022)
Article
Endocrinology & Metabolism
Emmanuelle Kuhn, Philippe Caron, Brigitte Delemer, Isabelle Raingeard, Herve Lefebvre, Gerald Raverot, Christine Cortet-Rudelli, Rachel Desailloud, Clementine Geffroy, Robin Henocque, Yves Brault, Thierry Brue, Philippe Chanson
Summary: The study aimed to define the medical reasons for treating patients with Pegvisomant (PEG) as monotherapy or combined therapy with somatostatin analogs (SAs). Results showed different patterns of treatment based on patient characteristics and response to therapy, with a focus on tumor concern and ease of normalizing IGF-I levels. Overall, the prospect of reducing PEG injection frequency favored the choice of combined therapy in certain cases.
Review
Endocrinology & Metabolism
Joan Gil, Mireia Jorda, Berta Soldevila, Manel Puig-Domingo
Summary: Epithelial-mesenchymal transition is a dynamic process that plays essential roles in both physiological and pathological processes, particularly in the growth and invasion of pituitary tumors. Studies have shown the association of EMT with resistance to somatostatin receptor ligands in the treatment of acromegaly.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
K. B. Daniel, A. de Oliveira Santos, R. A. de Andrade, M. B. F. Trentin, H. M. Garmes
Summary: The study on the application of GaDOTATATE PET/CT in acromegalic patients under SSA treatment found that evaluating the SUV max at the pituitary region through Ga-68-DOTATATE PET/CT may be useful in assessing drug response predictors without the need of tumoral tissue.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2021)
Article
Multidisciplinary Sciences
Joan Gil, Montserrat Marques-Pamies, Miguel Sampedro, Susan M. Webb, Guillermo Serra, Isabel Salinas, Alberto Blanco, Elena Valassi, Cristina Carrato, Antonio Pico, Araceli Garcia-Martinez, Luciana Martel-Duguech, Teresa Sardon, Andreu Simo-Servat, Betina Biagetti, Carles Villabona, Rosa Camara, Carmen Fajardo-Montanana, Cristina Alvarez-Escola, Cristina Lamas, Clara V. Alvarez, Ignacio Bernabeu, Monica Marazuela, Mireia Jorda, Manel Puig-Domingo
Summary: This study aimed to predict the response of acromegaly patients to somatostatin receptor ligands (SRL) using mathematical modeling and clinical information. Accuracy of patient stratification was significantly improved when the cohort was fragmented based on relevant clinical characteristics. The proposed stratification method based on tumor characteristics, sex, age, and multiple biomarkers achieved accuracies ranging from 71% to 95%. The use of data mining offers a promising approach for personalized medicine in acromegaly.
SCIENTIFIC REPORTS
(2022)
Review
Medicine, Research & Experimental
David Cella, Jennifer Evans, Marion Feuilly, Sebastian Neggers, Dirk Van Genechten, Jackie Herman, Mohid S. Khan
Summary: Based on a systematic literature review, LAN was favored over OCT in the treatment of acromegaly and NETs, with technical problems and pain during injections being the most influential factors in treatment experience.
ADVANCES IN THERAPY
(2021)
Article
Multidisciplinary Sciences
Katherine S. Chen, Courtney Lawhn-Heath, Spencer Behr, Roxanna Juarez, Julia Whitman, Alan Paciorek, Eric K. Nakakura, Nicholas Fidelman, Mary Uan-Sian Feng, Emily K. Bergsland, Mekhail Anwar
Summary: This study analyzed the oncologic outcomes after high-dose radiation in NENs patients at a tertiary hospital and found that local relapse-free survival was high, but the incidence of new metastases remained elevated, especially in PD-M patients. Most patients achieved a favorable response in the irradiated lesion after radiation therapy.